

Support Document 11: Blood Product and Convalescent Plasma Administration for Patients in SCDU

I. PRINCIPLE:

Patients admitted to the SCDU may need to receive blood products for hemostatic resuscitation. In the event of transfusion, Group O uncrossmatched red blood cells and group AB plasma products will be emergently released to the ordering physician. If AB plasma products are not available, group A products may be substituted.

II PROCEDURE:

- A. When it is determined that blood products need to be transfused to an SCDU patient, group O, RhD negative red blood cells and/or group AB plasma products will be issued. Group A plasma products may be substituted if group AB are not available. Blood type, antibody screen and crossmatch tests are not performed prior to standard blood product transfusions.
- B. If convalescent plasma is recommended for treatment, a historical blood type will be obtained if available and a forward ABO and RhD type will be performed by manual methods in the SCDU dedicated laboratory.

III Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks

The WHO has published the protocol for the use of convalescent whole blood or plasma as a treatment during patient care. You can find that document here:

http://apps.who.int/iris/bitstream/10665/135591/1/WHO_HIS_SDS_2014.8_eng.pdf?ua=1

Convalescent whole blood will be ABO-identical with the recipient; convalescent plasma will be ABO-compatible when possible.